There was a 53% decrease in the N-terminal (NT)-pro hormone BNP (NT-proBNP) (pooled mavacamten group; baseline: 713pg/mL) vs. a 1% decrease in the placebo group (baseline: 967pg/mL) (p=0.0005)
There was a 34% decrease in cardiac troponin-I (cTnI) in the pooled mavacamten group vs. a 4% increase in placebo (p=0.009)
In the mavacamten-treated participants, change in NT-proBNP at week 4 correlated with the change in cTnI at week 16 (rho=0.45, p=0.006)
90% of participants on mavacamten vs. 68% on placebo experienced an adverse event (AE), of which the majority were mild or moderate, self-limiting, and assessed by the investigator to be unrelated to treatment
Serious AEs occurred in 10% in mavacamten group and 21% in placebo group. Five participants on mavacamten had reversible reductions in LVEF to <45% at week 11-12 and met prespecified criteria for treatment discontinuation
Ho CY. Safety and Efficacy of Mavacamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: The MAVERICK-HCM Study. :17.